Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias
暂无分享,去创建一个
Tongtong Zhang | Deipei Wu | A. Sun | Jing-Ying Zou | Mingzhu Xu | Simao Huang | Sheng-li Xue | Haiqing Zhoub | Ming-zhu Xu
[1] Y. Natkunam,et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.
[2] C. Vetro,et al. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells , 2021, Journal of clinical medicine.
[3] Yungui Wang,et al. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia , 2021, Blood Cancer Journal.
[4] M. Konopleva,et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML , 2021, Journal of Hematology & Oncology.
[5] M. Konopleva,et al. An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia , 2021, American journal of hematology.
[6] Z. Estrov,et al. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia , 2020, American journal of hematology.
[7] M. Konopleva,et al. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias , 2020, Acta Haematologica.
[8] J. Novak,et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. , 2020, Blood.
[9] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[10] M. Amiot,et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. , 2017, Blood.
[11] M. Konopleva,et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients , 2017, Cancer.
[12] M. Konopleva,et al. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells , 2016, Science Translational Medicine.
[13] B. Druker,et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia , 2016, Science Translational Medicine.
[14] Yongping Song,et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development , 2015, Journal of Hematology & Oncology.
[15] J. Cayuela,et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.
[16] Y. Nojima,et al. Philadelphia chromosome‐positive mixed phenotype acute leukemia in the imatinib era , 2014, European journal of haematology.
[17] James M. Bogenberger,et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies , 2014, Leukemia.
[18] K. Coombes,et al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells , 2012, Annals of Hematology.
[19] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[20] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[21] M. Pettenati,et al. Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. , 2004, Leukemia research.
[22] A. Fielding. Philadelphia-positive acute lymphoblastic leukemia--is bone marrow transplant still necessary? , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.